Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism-Reference-Cited by-同舟云学术

Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism

Published:2022-01-21 Issue:3 Volume:8 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Krstic Jelena¹^ORCID,Reinisch Isabel¹,Schindlmaier Katharina¹,Galhuber Markus¹,Riahi Zina¹,Berger Natascha¹²^ORCID,Kupper Nadja¹^ORCID,Moyschewitz Elisabeth¹^ORCID,Auer Martina¹,Michenthaler Helene¹^ORCID,Nössing Christoph¹³^ORCID,Depaoli Maria R.⁴^ORCID,Ramadani-Muja Jeta⁴,Usluer Sinem⁴^ORCID,Stryeck Sarah⁴⁵⁶^ORCID,Pichler Martin⁷,Rinner Beate⁸,Deutsch Alexander J. A.⁹,Reinisch Andreas⁹¹⁰^ORCID,Madl Tobias⁴¹¹^ORCID,Chiozzi Riccardo Zenezini¹²¹³^ORCID,Heck Albert J. R.¹²¹³^ORCID,Huch Meritxell¹⁴^ORCID,Malli Roland⁴¹¹^ORCID,Prokesch Andreas¹¹¹^ORCID

Affiliation:

1. Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Division of Cell Biology, Histology and Embryology, Medical University of Graz, 8010 Graz, Austria.

2. Department of Obstetrics and Gynecology, Medical University of Graz, 8036 Graz, Austria.

3. Cancer Research UK Beatson Institute, Garscube Estate, Glasgow, UK.

4. Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Division of Molecular Biology and Biochemistry, Medical University of Graz, 8010 Graz, Austria.

5. Institute of Interactive Systems and Data Science, Graz University of Technology, 8010 Graz, Austria.

6. Know-Center GmbH, 8010 Graz, Austria.

7. Division of Clinical Oncology, Department of Medicine, Comprehensive Cancer Center Graz, Medical University of Graz, 8036 Graz, Austria.

8. Department for Biomedical Research, Medical University of Graz, Graz, Austria.

9. Division of Hematology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.

10. Division of Hematology, Department of Blood Group Serology and Transfusion Medicine Medical University of Graz, 8036 Graz, Austria.

11. BioTechMed-Graz, 8010 Graz, Austria.

12. Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, 3584CH Utrecht, Netherlands.

13. Netherlands Proteomics Center, 3584CH Utrecht, Netherlands.

14. Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.

Abstract

Cancer cells voraciously consume nutrients to support their growth, exposing metabolic vulnerabilities that can be therapeutically exploited. Here, we show in hepatocellular carcinoma (HCC) cells, xenografts, and patient-derived organoids that fasting improves sorafenib efficacy and acts synergistically to sensitize sorafenib-resistant HCC. Mechanistically, sorafenib acts noncanonically as an inhibitor of mitochondrial respiration, causing resistant cells to depend on glycolysis for survival. Fasting, through reduction in glucose and impeded AKT/mTOR signaling, prevents this Warburg shift. Regulating glucose transporter and proapoptotic protein expression, p53 is necessary and sufficient for the sorafenib-sensitizing effect of fasting. p53 is also crucial for fasting-mediated improvement of sorafenib efficacy in an orthotopic HCC mouse model. Together, our data suggest fasting and sorafenib as rational combination therapy for HCC with intact p53 signaling. As HCC therapy is currently severely limited by resistance, these results should instigate clinical studies aimed at improving therapy response in advanced-stage HCC.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference73 articles.

1. A framework for understanding and targeting residual disease in oncogene-driven solid cancers

2. Hallmarks of Cancer: The Next Generation

3. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

4. J. Krstic T. R. Pieber A. Prokesch in International Review of Cell and Molecular Biology (Elsevier Inc. ed. 1 2020) vol. 354 pp. 231–259.

5. Fasting and cancer: molecular mechanisms and clinical application

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis;Scientific Reports;2024-09-11

2. Suppression of neuronal CDK9/p53/VDAC signaling provides bioenergetic support and improves post-stroke neuropsychiatric outcomes;Cellular and Molecular Life Sciences;2024-09-05

3. Fasting in combination with the cocktail Sorafenib:Metformin blunts cellular plasticity and promotes liver cancer cell death via poly-metabolic exhaustion;Cellular Oncology;2024-07-11

4. FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma;Nature Communications;2024-05-07

5. Fasting-induced RNF152 resensitizes gallbladder cancer cells to gemcitabine by inhibiting mTORC1-mediated glycolysis;iScience;2024-05